{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:06:43Z","timestamp":1787162803151,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006388","name":"Geneva University Hospitals","doi-asserted-by":"publisher","award":["PRD-8-2017-2"],"award-info":[{"award-number":["PRD-8-2017-2"]}],"id":[{"id":"10.13039\/501100006388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cmi.2025.05.005","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T13:11:45Z","timestamp":1746796305000},"page":"1518-1525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inadequate imipenem dosing in patients with decreased kidney function: a global clinical pharmacokinetic study"],"prefix":"10.1016","volume":"31","author":[{"given":"Anh Quan","family":"Truong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim J.L.","family":"Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan Co","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Strojil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Preijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C.P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Huttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan D.T.","family":"Sassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.05.005_bib1","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically Ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.05.005_bib2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2025.05.005_bib3","author":"Sharp"},{"key":"10.1016\/j.cmi.2025.05.005_bib4","author":"Sharp"},{"key":"10.1016\/j.cmi.2025.05.005_bib5","series-title":"Antibiotic pharmacokinetic\/pharmacodynamic considerations in the critically Ill","first-page":"17","article-title":"Antibiotic pharmacodynamics","author":"Sime","year":"2018"},{"key":"10.1016\/j.cmi.2025.05.005_bib6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.05.005_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijantimicag.2014.12.017","article-title":"Augmented renal clearance, low \u03b2-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study","volume":"45","author":"Huttner","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.05.005_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2012.06.011","article-title":"Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data","volume":"40","author":"Yoshizawa","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.05.005_bib9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/bcp.12435","article-title":"Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens","volume":"78","author":"Couffignal","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2025.05.005_bib10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/psp4.12462","article-title":"Population pharmacokinetic analysis for imipenem-relebactam in healthy volunteers and patients with bacterial infections","volume":"8","author":"Bhagunde","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.cmi.2025.05.005_bib11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s40262-020-00859-1","article-title":"Population pharmacokinetics of imipenem in critically Ill patients: a parametric and nonparametric model converge on CKD-EPI estimated glomerular filtration rate as an impactful covariate","volume":"59","author":"de Velde","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2025.05.005_bib12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/phar.2597","article-title":"NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit","volume":"41","author":"Jaruratanasirikul","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2025.05.005_bib13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/ejhpharm-2022-003403","article-title":"Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients","volume":"31","author":"Bai","year":"2024","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.cmi.2025.05.005_bib14","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/pharmaceutics13040456","article-title":"Population pharmacokinetics and dose optimization of ceftazidime and imipenem in patients with acute exacerbations of chronic obstructive pulmonary disease","volume":"13","author":"Nguyen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cmi.2025.05.005_bib15","author":"Huttner"},{"key":"10.1016\/j.cmi.2025.05.005_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijantimicag.2014.05.011","article-title":"Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions","volume":"44","author":"Lip\u0161","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.05.005_bib17","first-page":"46","article-title":"Development of HPLC method for assay of imipenem and meropenem in plasma (Full-text in Vietnamese)","volume":"57","author":"Chi","year":"2017","journal-title":"Pharm J (Tap Duoc)"},{"key":"10.1016\/j.cmi.2025.05.005_bib18","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and Cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.05.005_bib19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.cmi.2025.05.005_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"10.1016\/j.cmi.2025.05.005_bib21","series-title":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products","year":"2016"},{"key":"10.1016\/j.cmi.2025.05.005_bib24","series-title":"Antibiotic pharmacokinetic\/pharmacodynamic considerations in the critically Ill","first-page":"73","article-title":"Hypoalbuminaemia and altered protein binding","author":"Brink","year":"2018"},{"key":"10.1016\/j.cmi.2025.05.005_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00134-014-3641-9","article-title":"Comparison of different equations to assess glomerular filtration in critically ill patients","volume":"41","author":"Carlier","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2025.05.005_bib26","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.13556","article-title":"Glomerular filtration rate correlation and agreement between common predictive equations and standard 24-hour urinary creatinine clearance in medical critically ill patients","volume":"10","author":"Wongpraphairot","year":"2022","journal-title":"PeerJ"},{"key":"10.1016\/j.cmi.2025.05.005_bib27","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3390\/pharmaceutics13122170","article-title":"Parametric and nonparametric population pharmacokinetic models to assess probability of target attainment of imipenem concentrations in critically Ill patients","volume":"13","author":"de Velde","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cmi.2025.05.005_bib28","article-title":"The performance of equations that estimate glomerular filtration rate against measured urinary creatinine clearance in critically Ill patients","volume":"2021","author":"Al-Dorzi","year":"2021","journal-title":"Crit Care Res Pract"},{"key":"10.1016\/j.cmi.2025.05.005_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.ackd.2017.10.003","article-title":"Pragmatic use of kidney function estimates for drug dosing: the tide is turning","volume":"25","author":"Hudson","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.cmi.2025.05.005_bib30","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.cmi.2025.05.005_bib31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2025.05.005_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00385-20","article-title":"Imipenem population pharmacokinetics: therapeutic drug monitoring data collected in critically Ill patients with or without extracorporeal membrane oxygenation","volume":"64","author":"Chen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.05.005_bib33","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/cid\/ciy790","article-title":"Renal dosing of antibiotics: are we jumping the gun?","volume":"68","author":"Crass","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.05.005_bib34","doi-asserted-by":"crossref","first-page":"383.e1","DOI":"10.1016\/j.cmi.2018.11.020","article-title":"Therapeutic drug monitoring of imipenem and the incidence of toxicity and failure in hospitalized patients: a retrospective cohort study","volume":"25","author":"Bricheux","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.05.005_bib35","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1128\/AAC.01318-06","article-title":"Population pharmacokinetics and pharmacodynamics of continuous vs. short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial","volume":"51","author":"Sakka","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.05.005_bib36","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1093\/infdis\/jiz651","article-title":"Association between pathophysiology and volume of distribution among patients with sepsis or septic shock treated with imipenem: a prospective cohort study","volume":"221","author":"Huang","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.05.005_bib37","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s00134-013-3088-4","article-title":"Clinical implications of antibiotic pharmacokinetic principles in the critically ill","volume":"39","author":"Udy","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2025.05.005_bib38","doi-asserted-by":"crossref","DOI":"10.1186\/cc10441","article-title":"Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of \u03b2-lactams","volume":"15","author":"Gon\u00e7alves-Pereira","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2025.05.005_bib39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/jac\/dky434","article-title":"Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models","volume":"74","author":"Dhaese","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.05.005_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","article-title":"The clinical relevance of plasma protein binding changes","volume":"52","author":"Roberts","year":"2013","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25002332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25002332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T21:51:56Z","timestamp":1758664316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25002332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1198743X25002332"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.05.005","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inadequate imipenem dosing in patients with decreased kidney function: a global clinical pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}